Structure Therapeutics (NASDAQ:GPCR) Now Covered by JPMorgan Chase & Co.

Analysts at JPMorgan Chase & Co. started coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The brokerage set an “overweight” rating and a $65.00 price target on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 78.67% from the stock’s previous close.

GPCR has been the topic of a number of other reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Friday, May 3rd. JMP Securities reaffirmed a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a research note on Friday, May 10th. Finally, Lifesci Capital reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics presently has an average rating of “Buy” and an average target price of $83.13.

Structure Therapeutics Trading Up 1.6 %

Shares of NASDAQ GPCR opened at $36.38 on Tuesday. The stock’s 50-day moving average is $38.73 and its 200 day moving average is $43.87. The stock has a market cap of $1.70 billion and a price-to-earnings ratio of -47.25. Structure Therapeutics has a 1-year low of $24.14 and a 1-year high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Friday, March 8th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. On average, analysts forecast that Structure Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Large investors have recently made changes to their positions in the business. Picton Mahoney Asset Management bought a new stake in shares of Structure Therapeutics in the 3rd quarter worth approximately $116,000. Sectoral Asset Management Inc. bought a new stake in shares of Structure Therapeutics during the fourth quarter valued at approximately $139,000. ADAR1 Capital Management LLC bought a new stake in shares of Structure Therapeutics during the fourth quarter valued at approximately $163,000. Washington University bought a new stake in shares of Structure Therapeutics during the third quarter valued at approximately $215,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Structure Therapeutics by 208.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,349 shares of the company’s stock valued at $177,000 after purchasing an additional 2,939 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.